Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nipocalimab→

Nipocalimab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2211985-36-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Neonatal Fc receptor (FcRn) blockerfully human IgG1 monoclonal antibody
Mechanism of action
Binds FcRn and prevents recycling of IgG, increasing lysosomal degradation and lowering circulating IgG concentrations, including pathogenic autoantibodies.
Indications / reported uses
  • Treatment of generalized myasthenia gravis in adults and paediatric patients aged 12 years and older who are anti-AChR or anti-MuSK antibody positive
  • Treatment of warm autoimmune haemolytic anaemia in adults and paediatric patients aged 12 years and older currently or previously treated with corticosteroids under the US IMAAVY indication (2026 label update)

Sources: US DailyMed — IMAAVY (nipocalimab-aahu), label updated 21 August 2026 · US FDA — IMAAVY approval for warm autoimmune haemolytic anaemia · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nipocalimab Environmental Risk Assessment (ERA) (the Nipocalimab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.